Perrigo Co PLC (PIG.BE)
| Previous close | 30.52 |
| Open | 30.56 |
| Bid | 30.69 x 0 |
| Ask | 30.80 x 0 |
| Day's range | 30.56 - 30.56 |
| 52-week range | 24.14 - 36.26 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswirePerrigo Announces Quarterly Dividend
Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024.
ZacksPerrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.
- PR Newswire
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that pharmaceutical company Esteve Healthcare, S.L. ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.
